Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus type b and meningococcal group C conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Hib-MenC vaccine (marketed under the brand name Menitorix) is a combination conjugate vaccine developed by GSK Biologicals to provide active immunization against invasive diseases caused by Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroup C (MenC) in infants and toddlers. The vaccine consists of Hib capsular polysaccharide (polyribosylribitol phosphate, PRP) and MenC capsular polysaccharide, both individually conjugated to tetanus toxoid (TT) as a carrier protein to enhance immunogenicity in young children. It was widely used in routine childhood immunization schedules, such as in the United Kingdom and Australia, typically administered as a booster dose at 12 months of age. In 2022, GSK announced the discontinuation of Menitorix for commercial reasons, with the vaccine phased out of routine schedules by 2025. In some clinical trial contexts, related investigational formulations containing serogroups A and C (Hib-MenAC) were also evaluated (e.g., in combination with Tritanrix-HepB).
- Brand names
- Menitorix
- Other names
- Hib-MenC vaccineHib-MenCHib/MenCHib-MenACHib-MenAC vaccine
02
Targets
PRP (Haemophilus influenzae type b capsular polyribosylribitol phosphate)Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)
Beyond the preview
Go deeper on haemophilus type b and meningococcal group C conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus type b and meningococcal group C conjugate vaccine.